- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05227053
STOPP AF Første studie etter godkjenning
STOP AF First Post-Godkjenningsstudie, et tillegg til Cryo Global Registry
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The STOP AF First Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The STOP AF First PAS is a prospective, global, multi-center, observational trial. The purpose of the study is to describe long-term clinical performance and safety data in the recurrent symptomatic paroxysmal AF population treated with Arctic Front™ and Freezor™ MAX Families of cardiac cryoablation catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System) as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. This PAS is a condition of the pre-market approval order (P100010/S110) by the U.S. Food and Drug Administration.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Heart Institute
-
-
Connecticut
-
Stamford, Connecticut, Forente stater, 06905-5522
- Cardiology Associates of Fairfield County
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, Forente stater, 33756
- BayCare Medical Group Cardiology
-
Davie, Florida, Forente stater, 33328
- Heart Rhythm Solutions
-
-
Iowa
-
West Des Moines, Iowa, Forente stater, 50266
- Iowa Heart
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Forente stater, 02747
- Southcoast Health System
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202-2608
- Henry Ford Heart & Vascular
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45219
- The Lindner Research Center
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138
- Stern Cardiovascular Foundation
-
-
Texas
-
Dallas, Texas, Forente stater, 75231
- Texas Health Research and Education Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ cardiac cryoablation catheter System.
Beskrivelse
Inclusion Criteria:
- Subject has been diagnosed with symptomatic paroxysmal AF
- Subject is ≥ 18 years of age or minimum age as required by local regulations
- Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.
- Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements
Exclusion Criteria:
History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1
. Subjects under the following conditions may be included in the study:
-
Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of <4 weeks prior to the index PVI procedure)
-
Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
-
A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.
- Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)
- Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
- Subject with exclusion criteria required by local law
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)
Tidsramme: 36 months
|
Estimate the 36-month freedom from Atrial Fibrillation (AF) /atrial flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ cardiac cryoablation catheter System. |
36 months
|
|
Freedom from Primary Safety Events
Tidsramme: 12 months
|
Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ cardiac cryoablation catheter System through 12-months. |
12 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Khaldoun Tarakji, MD, Medtronic CAS Chief Medical Officer
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STOP AF First PAS
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .